Nilotinib: A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias

Elias Jabbour, Samih El Ahdab, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia (CML). Imatinib mesilate therapy has significantly improved the prognosis of CML. A minority of patients in chronic-phase CML - and more patients in advanced phases - are resistant to imatinib, or develop resistance during treatment. This is attributed, in 40 - 50% of cases, to the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Nilotinib (Tasigna®) is a novel potent selective oral kinase inhibitor. Preclinical and clinical investigations demonstrate nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure.

Original languageEnglish (US)
Pages (from-to)1127-1136
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number7
StatePublished - Jul 2008
Externally publishedYes


  • ALL
  • CML
  • Imatinib
  • Intolerance
  • Nilotinib
  • Ph-positive
  • Resistance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Nilotinib: A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias'. Together they form a unique fingerprint.

Cite this